chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Administration of expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine). On 15-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Administration of expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  Treatment information was not provided.
Tinnitus; This is a spontaneous report received from a contactable consumer, the patient. A 65 years old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: EL9265) via an unspecified route in left arm on 22Feb2021, at 09:15 AM as a second single dose for COVID-19 immunisation. The patients medical history included dupuytren's Contracture. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN), received in two weeks of vaccination. It was reported that, prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. It was reported that the patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine and no known allergies to medications, food or other products. On 01Mar2021, the patient experienced developed moderate-severe tinnitus in left ear (patient stated that he had minor tinnitus for many years, but barely noticeable. About 1 week after second dose of vaccine). The patient did not receive any treatment for events. The clinical outcome of tinnitus was not recovered.   No follow-up attempts are possible. No further information is expected.
The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 3-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004973: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
I cant take deep breaths without mildly coughing; I cant take deep breaths without mildly coughing; my throat felt weird; it felt like a big lump was in my left side throat; Now right side is swelling up; My neck was obviously swollen from even the outside appearance; This is a spontaneous report from a contactable consumer (patient) via COVAES. This 52-year-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number ER8731) via an unspecified route of administration in the left arm on 14Apr2021 at 09:45 (at 52-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history or concomitant medications. Prior to vaccination the patient had not received any other vaccines within 4 weeks, had no known allergies, and was not diagnosed with COVID-19 prior to vaccination. The patient reported that within about 5-10 minutes of receiving her first Pfizer COVID shot, her throat felt weird, and she thought she just needed some water since she had her mask on. She waited until her time was up and then was heading to her car and turned around because it felt like a big lump was in her left side throat. The emergency medical technician (EMT) desk gave her diphenhydramine hydrochloride (BENADRYL) and checked oxygen. They told her to wait and wanted to monitor her, then the right side was swelling up. She reported her neck was obviously swollen from even the outside appearance. They put her in the ambulance and took her to emergency room (ER). At the ER she received an epinephrine shot in her right arm and a dose of steroids intravenously (IV) in her left arm. They monitored her for 4 hours and let her go home. The patient was told not to get the second shot and was told to take two diphenhydramine hydrochloride three times a day and two prednisone for four days. The patient reported the next day she went to work but found it difficult to keep her mask on, which she usually wore for 8 hours a day. She had been feeling okay but now (as of 18Apr2021) three days later, she couldn't take deep breaths without mildly coughing. The clinical outcomes of couldn't take deep breaths without mildly coughing were not recovered; the outcomes of the other events were recovered with sequelae in Apr2021. Since vaccination the patient had not been tested for COVID-19.
At two (2) week mark, patient began experiencing daily migraine headaches. Pain became severe. Daily pain lasted approximately 2 weeks.  When migraines subsided, patient noticed that smell and taste were "off".  Had experienced loss of smell and taste with COVID infection but this was different.  Now many foods are described as tasting like petroleum jelly.  Many smells are described as burning oil.  Rancid or rotten items are described as sweet smelling.  Smell and taste so bad that has almost induced vomiting.
the second dose has not been administered yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose with batch number 397A2, expiry date 27th May 2022, on 30th October 2019).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: the second dose has not been administered yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt date: 27-Mar-2023 The reporter asked should restart the vaccine series. The vaccine administration facility was the same as primary reporter. The reporter did not consent to follow-up. The Vaers details were reported for the 1st dose of Shingrix. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Swollen lymph nodes on left side for over a month. Pain shooting down left arm with tingling and numbness lasting over a month so far. Sometimes pain shoots up into neck and into armpit and left side of abdomen. Heart rate also seems to race at times.
Information has been received from a RN concerning an adult pt with diabetes who in approx Feb 2006 was vaccinated IM with a 0.5ml dose of pneumococcal 23v polysaccharide vaccine (lot650302/1039P). Subsequently, the pt developed an injection site reaction to include redness, swelling and pain at the injection site. Unspecified medical attention was sought. At the time of the report, the pt was recovering. Additional information has been requested.
Patient received the shot in the afternoon around 2:45pm on 10/19/17.Unsure of time frame, but when patient left to go home, she felt faint, noticed tongue began to swell and lymph nodes felt tender. Patient took a Benadryl as soon as she noticed these symptoms. Today, on 10/21/17 she called the pharmacy and reported this. She states it still feels a bit swollen but has subsided. Will continue to take Benadryl as it takes time to recover. She states she has gone through this before due to a med-related allergic reaction, so she knows when to seek urgent treatment. She will contact her primary care provider to notify of this reaction as well.
pt recv vax 9JAN96 & 11JAN96 pt devel chicken pox;the nurse reported that the pt brother was also vaccinated w/varicella vax & also devel chicken pox #96012060;
The pt developed erythema, edema, dry skin, warmth and tenderness at injection site (right deltoid). Initially indurated. Given Amoxil 600 mg bid x 10 days.
Local redness, swelling noted ? some difficulty moving arm. Took tylenol felt better. By 2/6/01 arm @ point of injection very swollen. Saw Dr who placed her on Keflex for 5 days. (6 inch swollen).
Patient had gotten Pfizer in hospital but stated she was her to get her 2nd dose of vaccine and did not have or had lost her card.  She did not tell anyone that she had got Pfizer, staff found this out after questioning her further and realized it was pfizer that she received for first dose.  Patient inadvertently received Moderna today as her second dose.
Patient received booster of Moderna (025ml) on 10/25/21. According to modernatx website specific lot number has an exp of of 10/24/21.
left arm soreness; Lack of energy; This is a spontaneous report from a contactable consumer (patient). A 79-years-old female patient received second dose of bnt162b2 (BNT162B2 Pfizer-BioNTech COVID-19 Vaccine; Solution for injection), via an unspecified route of administration on 11Feb2021 as single dose for covid-19 immunization. Medical history included bronchitis and illness from Dec2019 to an unknown date. Concomitant medications were not reported. The patient experienced left arm soreness, lack of energy on an unspecified date. The reporter said that she become very ill in dec2019 while on vacation in (place name), went to walk-in clinic twice. no pneumonia though coughing, horrible wheezing, told me it was probably bronchitis. given numerous drugs, still doctoring when and returned home. more drugs. no energy for 2-3 months. had been told lots of sickness in (place name) when she was there. heart and lungs checked and ok. often wondered if she had covid. woman across aside from me on plane coughed all the way to (place name). 3 days later she was sick. The outcome of the events was unknown.
FELT SICK; VERY TIRED; ADVERSE EVENT; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no known allergies. Patient was not having any medical history. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On 09-MAY-2022, the patient experienced adverse event. On an unspecified date, the patient experienced felt sick, and very tired. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from adverse event on 09-MAY-2022, and the outcome of very tired and felt sick was not reported. This report was non-serious.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 42-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Apr2021 as dose 1, single (Lot number: ER8729), in left arm and on 26Apr2021 as dose 2, single (Lot number: ER8735) at the age of 41 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 31Oct2021 as dose 3 (booster), single (Lot number: 071F21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Migraine with aura" (unspecified if ongoing); "Prosopagnosia" (unspecified if ongoing); "High BMI" (unspecified if ongoing), notes: High BMI; "Dose:2, 1 Pfizer/Dose:3 Moderna" (not ongoing), notes: Dose:2, 1 Pfizer/Dose:3 Moderna. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset May2022, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (11May2022) Positive; (19May2022) Negative; (20May2022) Negative; (21May2022) Negative; (22May2022) Negative; (23May2022) Positive; (23May2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. The clinical course included anti viral details: Product: COVID 19 Treatment, brand: Paxlovid, treatment start date: 3May2022, treatment stop date: 11May2022 and indication: Treatment of COVID-19. Tested positive on 11May2022, took first (PM) dose of Paxlovid on 12May2022. Symptoms improved greatly. Took final dose of Paxlovid on 18May2022 (AM). Tested negative on 19May2022, 20May2022, 21May2022 and 22May2022. Symptoms returned and tested positive on 23May2022 and 24May2022.  No follow-up attempts are possible, no further information expected.
INR has fluctuated from normal 2.6 down to 1.6 up to critical 6.4 since  I received injection.  My Dr has changed my warfin dosage several times and taken me off for short periods to try to level it.  This has all been since I received the wrong covid shot at the above named pharmacy.
Fatigue, headache and nausea experienced four days after receiving the dose 1 COVID vaccine.
Report 20010039091 described headache and nausea in a 42 year old female who received hepatitis B vaccine recombinant (Engerix-B) for prophylaxis of hepatitis B. Reportedly, the vaccinee had no allergies or medical history. Reportedly, she took no concomitant medications. There was no illness at the time of vaccination. On 12/21/2000, the vaccinee received her first 20 mcg IM dose of Engerix-B. Post-vaccination, on 12/21/2000, the vaccinee experienced severe nausea and headache. These adverse events resolved on 12/21/2000. Engerix-B was stoped due to the adverse events. As of 03/13/2001, the outcome of the adverse events is resolved. The reporter has reported these adverse events directly to VAERS.
Late 2nd dose on 09-jun-2022 1st dose on 22-dec-2021; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 34-year-old male patient who received HAB (Twinrix) (batch number 4F3YY, expiry date 1st January 2023) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (the patient received 1st dose of Twinrix on 22nd December 2021).   On 9th June 2022, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On 9th June 2022, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 9-JUN-2022 Reporter's Comments: On the day of reporting, the patient received a late 2nd dose for Twinrix. The vaccine administration facility was the same as primary reporter. The reporter give consent to follow up. Additional supportive information: The patient received 2nd dose later than recommended interval, which led to lengthening of vaccination schedule.
Patient is a 75-year-old female with past medical history of hypertension, hypothyroidism, dementia, with additional history as noted below presented to hospital s/p fall and with a complaint of fatigue.  Patient was subsequently found to be positive for COVID-19.  During her stay there was concern for conversion to new onset A. fib and therefore consultation was placed to cardiology for further evaluation/recommendations. Patient discharged home with skilled home care, with the following services Home PT, Skilled nursing
No adverse event; Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 12-Oct-2022, the patient experienced ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster).    No concomitant medications were provided. No treatment medication was provided. This case contains information for the 1st adult patient out of 15 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-658149, US-MODERNATX, INC.-MOD-2022-658150, US-MODERNATX, INC.-MOD-2022-658152, US-MODERNATX, INC.-MOD-2022-658154, US-MODERNATX, INC.-MOD-2022-658155, US-MODERNATX, INC.-MOD-2022-658156, US-MODERNATX, INC.-MOD-2022-658157, US-MODERNATX, INC.-MOD-2022-658158, US-MODERNATX, INC.-MOD-2022-658159, US-MODERNATX, INC.-MOD-2022-658160, US-MODERNATX, INC.-MOD-2022-658161, US-MODERNATX, INC.-MOD-2022-658162, US-MODERNATX, INC.-MOD-2022-658168, US-MODERNATX, INC.-MOD-2022-658173 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-658149:Adult patient 2 US-MODERNATX, INC.-MOD-2022-658150:Adult patient 3 US-MODERNATX, INC.-MOD-2022-658152:Adult patient 4 US-MODERNATX, INC.-MOD-2022-658154:Adult patient 5 US-MODERNATX, INC.-MOD-2022-658155:Adult patient 6 US-MODERNATX, INC.-MOD-2022-658156:Adult patient 7 US-MODERNATX, INC.-MOD-2022-658157:Adult patient 8 US-MODERNATX, INC.-MOD-2022-658158:Adult patient 9 US-MODERNATX, INC.-MOD-2022-658159:Adult patient 10 US-MODERNATX, INC.-MOD-2022-658160:Adult patient 11 US-MODERNATX, INC.-MOD-2022-658161:Adult patient 12 US-MODERNATX, INC.-MOD-2022-658162:Adult patient 13 US-MODERNATX, INC.-MOD-2022-658168:Adult patient 14 US-MODERNATX, INC.-MOD-2022-658173:Adult patient 15
I began to feel ill on that Wednesday morning. I had had a bilateral mastectomy in Nov of 2020, and tissue expanders are still in place. I reached a fever of 103.6 and had pain and extreme redness in my right tissue expander. I also had all axillary lymph nodes removed from that side in December 2020. On Friday I was still feeling ill and noticed redness, so I immediately contacted my doctor and was instructed to meet him at the hospital. I was admitted and placed on antibiotics and had my tissue expander removed The next morning after no improvement from antibiotic infusion. I had a wound vac placed and stayed in the hospital for one week and had my expander replaced on that following Saturday.  I am not planning on taking the second shot.
DEMAND ISCHEMIA CHRONIC HYPOXEMIC RESPIRATORY FAILURE HYPOXIA 11/5/2022 &  11/26/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
7 month old was inadvertently administered a dose of Kinrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 7-month-old patient who received DTPa-IPV (Kinrix) for prophylaxis.   On 20-OCT-2023, the patient received Kinrix. On 20-OCT-2023, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 7 month old was inadvertently administered a dose of Kinrix). The outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 23-OCT-2023 It was reported that a 7 month old was inadvertently administered a dose of Kinrix which led to inappropriate age at vaccine administration. The reporter was unable to provide any vaccine or patient details. The reporter did not consent to follow up.